About Axel Hoos
Axel Hoos is a board member at NextPoint Therapeutics.
Axel Hoos first appears on SEC filings in 2024.
Experience
This experience comes from Axel Hoos's profile and from SEC filings. For roles taken from filings, the years are when the filings name Axel Hoos in the role, so the role may have started earlier or lasted longer.
NextPoint Therapeutics, Inc. Current
Board Member
Director, Board of Directors (2023 – Present)
2023 – Present · Cambridge, MA
Develops targeted cancer treatments for patients with solid tumors.
ST
Scorpion Therapeutics Current
Former CEO
2021 – Present
GS
GSK Current
Former SVP and R&D Governance Chair, Oncology
2012 – Present
SI
Sabin Vaccine Institute Current
Member, Board of Trustees
2006 – Present
CC
Cancer Research Institute (CRI) Current
Co-Director Cancer Immunotherapy Consortium
2004 – Present
TI
TCR² Therapeutics Inc.
Director, Board of Directors
2020 – 2023
IL
Imugene Limited
Co-Founder, and Non-Executive Director
2012 – 2021
BS
Bristol Myers Squibb
Global Medical Lead, Immunology/Oncology
2005 – 2012
AG
Agenus
Senior Director, Clinical Development
2001 – 2005
Key Colleagues at Startups
The people Axel Hoos works with at each company, as listed on that company's latest Form D.
NextPoint Therapeutics, Inc. · Form D, Jul 30, 2026
Paulina Hill
Board Member
Ivan Cheung
Chief Executive Officer and director
R. Jacob Vogelstein
Board Member
JL
Jeffrey Lacey
Secretary & Treasurer
Brian Shuster
Board Member
Detlev Biniszkiewicz
Chairman of the Board
Rakhshita Dhar
Board Member